SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Biotechnology Cancer Cures
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote ()4/12/1999 3:25:00 PM
From: Dr. Bob  Read Replies (1) of 226
 
SANG specializes in cancer drugs; has cyclosporine and thymoglobulin on the market, and is developing a unique distribution system. Trades at only 12 times estimated 2000 earnings. I'd put it on my short list for this sector just because it's a cinch to earn money soon. May well put it in a similar position to Amgen, where it can begin to acquire other promising drugs or companies rather than needing their own pipeline to produce everything.

Bob
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News